Loading
ALX Oncology Holdings Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 04 Feb 2026.
ALX Oncology Holdings Inc: what insiders have been doing
ALX Oncology Holdings Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 4 insiders have disclosed 9 filings since 18 October 2025.
Open-market activity splits into 1 purchase totalling €4.2M and 7 sales totalling €37k; 1 insider sit on the buying side and 3 insiders on the selling side. The net balance comes to €4.2M on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 senior executive. One trade stands out by size: a purchase of €4.2M from Goodman Corey S, disclosed on 4 February 2026.
The most recent open-market purchase was published on 4 February 2026, 256 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (5,808 companies, median 19 filings), a count of 9 filings is below the norm. The full history, which starts in 2021, counts 6 purchases against 54 sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
100
Thresholds
n/a
Buy Volume
€4M
6 ops. · all time
Sell Volume
€5M
54 ops. · all time
Who traded when
BuySaleShelly Pinto9 sales
Jason Lettmann1 buy4 sales
Jaume Pons2 sales
Shelly Wong2 sales
Corey S. Goodman1 buy
Harish Shantharam1 buy
+1 other insider
Since the insiders bought
- +1.5%Entry US$2.06 · Close at T+90 US$2.09
- +37.2%Entry US$1.21 · Close at T+365 US$1.66
- +98.1%Entry US$1.03 · Close at T+365 US$2.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.89
Analyst consensus
5 analysts1.43/5
US$4.00Target US$4.60(+414%)US$6.00
Income statement
EBITDA-US$99.4M
Net income-US$101.7M0.0% margin
Valuation
PER (forward)-3.7x
P/Book0.9x
Beta0.48
Balance sheet & cash
Market capUS$123.7M
Total debtUS$9.7M
Free Cash Flow-US$84.4M
Debt / Equity8%
Profitability & ownership
ROE-80.6%
ROA-40.4%
% insiders0.9%
% institutions84.7%
Last declaration on 18 August 2026
Declarations100 total
2,230 shares@ US$1.930.0023% mcap0.3% of flowCommon StockSEC:0001193125-26-355764:0
573 shares@ US$1.930.0006% mcap27.5% of flowCommon StockSEC:0001193125-26-355761:0
1,404 shares@ US$2.040.0015% mcap72.5% of flowCommon StockSEC:0001193125-26-296246:0
12,311 shares@ US$2.171.6% of flowCommon StockSEC:0001193125-26-119705:0
903 shares@ US$2.171.2% of flowCommon StockSEC:0001193125-26-119703:0
565 shares@ US$2.270.8% of flowCommon StockSEC:0001193125-26-061313:0
2,201 shares@ US$2.270.3% of flowCommon StockSEC:0001193125-26-060037:0
3,184,713 shares@ US$1.57100.0% of flowCommon StockSEC:0001278411-26-000002:0
Canonical exit: 3 May 2026 (T+90)
3,925 shares@ US$1.112.6% of flowCommon StockSEC:0001193125-26-006374:0
21,070 shares@ US$1.0661.3% of flowCommon StockSEC:0001193125-25-207432:0
Canonical exit: 15 Dec 2025 (T+90)
75,000 shares@ US$0.7787100.0% of flowCommon StockSEC:0000950170-25-110434:0
Canonical exit: 16 Nov 2025 (T+90)
2,382 shares@ US$0.64040.1% of flowCommon StockSEC:0000950170-25-110099:0
611 shares@ US$0.64040.2% of flowCommon StockSEC:0000950170-25-110102:0
2,011 shares@ US$0.45010.5% of flowCommon StockSEC:0000950170-25-094613:0
1,532 shares@ US$0.430.4% of flowCommon StockSEC:0000950170-25-092232:0
42,000 shares0Common StockSEC:0001415889-25-008417:0
3,000 shares0Common StockSEC:0001415889-25-008428:0
550 shares@ US$1.15020.4% of flowCommon StockSEC:0001415889-25-005071:0
2,159 shares@ US$1.15020.2% of flowCommon StockSEC:0001415889-25-005067:0
1,326 shares@ US$1.15020.1% of flowCommon StockSEC:0001415889-25-005069:0
2,221 shares@ US$1.802.8% of flowCommon StockSEC:0001415889-25-001120:0
10,796 shares@ US$1.58020.7% of flowCommon StockSEC:0001415889-25-000123:0
1,426 shares@ US$1.58021.5% of flowCommon StockSEC:0001415889-25-000132:0
30,000 shares@ US$1.5468100.0% of flowCommon StockSEC:0001415889-24-028247:0
Canonical exit: 2 Mar 2025 (T+90)
1,365 shares@ US$2.580.2% of flowCommon StockSEC:0001415889-24-021480:0
25 of 100 declarations
About ALX Oncology Holdings Inc
ALX Oncology Holdings Inc. (ticker: ALXO) is a United States-based biotechnology company listed on the NASDAQ, and it operates as a clinical-stage oncology developer rather than a commercial-stage drug maker. Headquartered in South San Francisco, California, the company is focused on immuno-oncology programs designed to help the immune system recognize and attack cancer. ALX Oncology was formed as a Delaware corporation on April 1, 2020, while the company’s operating history dates back to its founding in 2015, according to corporate communications. ([alxoncology.com](https://alxoncology.com/about-us/?utm_source=openai))
The company’s lead asset is evorpacept, a novel CD47-targeted investigational therapy. In practical terms, ALX is pursuing a “don’t eat me” signal blockade strategy: by inhibiting CD47, evorpacept is intended to help the innate immune system identify tumor cells and may enhance the activity of other anti-cancer agents. The pipeline has been built around combination regimens, especially with anti-cancer antibodies, antibody-drug conjugates (ADCs), and selected checkpoint inhibitor approaches. More recently, management has emphasized clinical activity in HER2-positive tumors, gastric and gastroesophageal junction cancers, breast cancer, and certain hematologic malignancies. The company is also advancing ALX2004, an EGFR-targeted ADC that received U.S. FDA IND clearance in 2025 and entered Phase 1 development. ([alxoncology.com](https://alxoncology.com/our-approach/evorpacept/?utm_source=openai))
Read moreShow less
From a competitive standpoint, ALX Oncology is operating in a highly crowded and scientifically demanding area of cancer drug development. Its investment case depends on whether evorpacept can show a differentiated efficacy-and-safety profile versus other immuno-oncology and targeted therapy combinations, while also translating early clinical signals into registrational opportunities. The most recent updates in 2025 and 2026 highlighted positive data in HER2-positive gastric cancer, indolent B-cell non-Hodgkin lymphoma, and HER2-positive breast cancer, while some prior studies in head and neck cancer did not meet their primary endpoints. That mix of promising signals and clinical setbacks is typical for a development-stage biotech and should be seen as part of the risk/reward framework. ([ir.alxoncology.com](https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-presents-positive-updated-data-aspen-06-phase-2/?utm_source=openai))
Geographically, the company is centered in South San Francisco with a U.S. operating base, while its clinical footprint extends through investigator-sponsored studies, academic collaborations, and multi-center trials. Recent company milestones include additional clinical disclosures at major oncology conferences, continued progress on ALX2004, and a 2026 equity offering that strengthened the balance sheet and funded ongoing development. For investors in France, Belgium, and Switzerland, ALXO should therefore be viewed as a speculative NASDAQ-listed oncology name whose valuation will be driven primarily by clinical readouts, pipeline execution, and future financing needs rather than current product sales. ([ir.alxoncology.com](https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-reports-first-quarter-2026-financial-results-and?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
